Johnson & Johnson’s Protagonist Therapeutics PTGX Stock Holding History

Johnson & Johnson’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$300M	Hold	2,449,183	–	–	37.59%	1
2026 Q1	$258M	Hold	2,449,183	–	–	39.57%	1
2025 Q4	$214M	Hold	2,449,183	–	–	38.54%	1
2025 Q3	$163M	Hold	2,449,183	–	–	32.29%	1
2025 Q2	$136M	Hold	2,449,183	–	–	40.83%	1
2025 Q1	$118M	Hold	2,449,183	–	–	34.65%	1
2024 Q4	$94.5M	Hold	2,449,183	–	–	24.48%	1
2024 Q3	$110M	Hold	2,449,183	–	–	25.79%	1
2024 Q2	$84.9M	Hold	2,449,183	–	–	21.18%	1
2024 Q1	$70.9M	Hold	2,449,183	–	–	1.61%	4
2023 Q4	$56.2M	Hold	2,449,183	–	–	1.28%	3
2023 Q3	$40.9M	Hold	2,449,183	–	–	15.05%	3
2023 Q2	$67.6M	Hold	2,449,183	–	–	21%	1
2023 Q1	$56.3M	Hold	2,449,183	–	–	18.32%	2
2022 Q4	$26.7M	Hold	2,449,183	–	–	7.77%	5
2022 Q3	$20.6M	Hold	2,449,183	–	–	6.08%	6
2022 Q2	$19.4M	Hold	2,449,183	–	–	4.95%	8
2022 Q1	$58M	Hold	2,449,183	–	–	10.96%	3
2021 Q4	$83.8M	Hold	2,449,183	–	–	9.54%	3
2021 Q3	$43.4M	Buy	+2,449,183	New	+$104M	3.81%	7

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Johnson & Johnson's PTGX Position: Q2 2026 in Review

Johnson & Johnson held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 2,449,183 shares worth $300M. The position accounts for 37.59% of the portfolio, ranked #1.

Johnson & Johnson first reported a position in PTGX in Q3 2021 and has held it in 20 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Johnson & Johnson held 2,449,183 shares of Protagonist Therapeutics worth $300M as of Q2 2026.
Johnson & Johnson left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 37.59% of Johnson & Johnson's portfolio in Q2 2026, its #1 holding.
Johnson & Johnson first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 20 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.